

Amendments to the Claims

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Original) A method for treating an autoimmune disorder in a patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from said patient;
- b) treating said cells with a regulatory composition to generate regulatory T cells; and
- c) reintroducing said regulatory T cells to said patient to suppress an aberrant immune response.

25. (Original) A method according to claim 24 wherein said aberrant immune response is a cell-mediated autoimmune disease selected from the group consisting of Hashimoto's disease, polymyositis, disease inflammatory bowel disease, multiple sclerosis, diabetes mellitus, rheumatoid arthritis, and scleroderma.

26. (Original) A method for treating an autoimmune disorder in a patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from said patient;
- b) treating said cells with a regulatory composition to induce said cells to produce immunosuppressive levels of TGF- β ; and
- c) reintroducing said cells to said patient to suppress aberrant immune responses.

11
12
13
14
15
16
17. (Currently Amended) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises TGF- β .

18. (Currently Amended) A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises TGF- β .

19. (Original) A method according to claim 24 or 26 wherein saPd PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises TGF- β .

20. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises TGF- β and IL-2.

21. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises TGF- β and IL-2.

22. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises TGF- β and IL-2.

~~10~~ 33. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

~~11~~ 34. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

~~12~~ 35. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

~~13~~ 36. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

~~14~~ 37. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

~~15~~ 38. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

~~16~~ 39. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

~~17~~ 40. (Original) A method according to claim ~~24~~ or ~~26~~ wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

Contd

18
41. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

19
42. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD3.

20
43. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD3.

B1
21
44. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD3.

22
45. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise TandK cells and said regulatory composition comprises TGF- β .

23
46. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise TandK cells and said regulatory composition comprises TGF- β and IL-2.

24
47. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise TandK cells and said regulatory composition comprises TGF- β , IL-2 and anti-CD2.

25
48. (Original) A method according to claim 24 or 26 wherein said PBMCs comprise TandK cells and said regulatory composition comprises TGF- β , IL-2 and anti-CD3.

USSN: 10/028,944

Filing Date: December 21, 2001

26
40. (Original) A method according to claim 26 wherein said aberrant immune response is an antibody mediated disease selected from the group consisting of pemphigus vulgaris, myasthenia gravis, hemolytic anemia, thrombocytopenia purpura, Grave's disease, dermatomyositis and Sjogren's disease.